Holliston

Holliston biotech Biostage has secured another investment, $1 million from a private investor named Jinhui Liu.

A Chinese investor and biotech executive has been appointed to be chairman of Holliston-based Biostage's board of directors.

Holliston biotech has appointed a Connecticut children's hospital doctor to its scientific advisory board less than a month after the company closed on a $100,000 investment from the same hospital.

Holliston medical device maker Harvard Bioscience is set to acquire a Minnesota biomedical firm for $70 million, simultaneous to a $20-million sale of Harvard's subsidiary Denville Scientific.

What's it like to bring a company back to life after near bankruptcy? Jim McGorry, CEO of Holliston biotech Biostage, explains how the company never lost faith.

Holliston-based Biostage announced Wednesday the closing of a $4.2-million private investment primarily with a Chinese investment group and a Connecticut children's hospital.

A Holliston medical marijuana facility has received final approval from Massachusetts health officials to begin cultivation operations.

In order to complete a $4-million deal with a private investor and save the company from insolvency, Holliston biotech Biostage has performed a 20:1 reverse stock split.

Two months after laying off more than 70 percent of its workforce and being delisted from Nasdaq, Holliston biotech Biostage announced on Thursday a $4-million private investment.

Holliston biotech Biostage will officially be delisted on Dec. 18 from the Nasdaq Stock Excahnge, after failing to keep a high enough stock price.